C4 Therapeutics (CCCC) Projected to Post Quarterly Earnings on Thursday

C4 Therapeutics (NASDAQ:CCCC) is anticipated to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect C4 Therapeutics to post earnings of ($0.43) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 27, 2026 at 12:30 PM ET.

C4 Therapeutics Stock Up 4.4%

NASDAQ:CCCC opened at $1.91 on Thursday. The company has a fifty day simple moving average of $2.06 and a two-hundred day simple moving average of $2.35. The company has a market cap of $185.10 million, a price-to-earnings ratio of -1.14 and a beta of 2.96. C4 Therapeutics has a 52 week low of $1.09 and a 52 week high of $3.65.

Analyst Ratings Changes

A number of research firms recently issued reports on CCCC. TD Cowen initiated coverage on C4 Therapeutics in a report on Tuesday, December 2nd. They issued a “buy” rating for the company. Barclays reduced their price target on C4 Therapeutics from $10.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of C4 Therapeutics in a research report on Wednesday, January 21st. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, C4 Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $7.25.

Institutional Investors Weigh In On C4 Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CCCC. Zacks Investment Management purchased a new position in C4 Therapeutics in the third quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of C4 Therapeutics in the 3rd quarter valued at $43,000. Engineers Gate Manager LP grew its position in shares of C4 Therapeutics by 49.9% in the 4th quarter. Engineers Gate Manager LP now owns 24,416 shares of the company’s stock valued at $47,000 after buying an additional 8,130 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in C4 Therapeutics during the 1st quarter worth $43,000. Finally, Voleon Capital Management LP purchased a new stake in C4 Therapeutics in the third quarter valued at $63,000. Institutional investors and hedge funds own 78.81% of the company’s stock.

About C4 Therapeutics

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.